Locus 1q21 Gene expression changes in atopic dermatitis skin lesions: deregulation of small proline-rich region 1A.
BACKGROUND
Discovery of the significant impact of filaggrin (FLG) mutations on the genetic predisposition to atopic dermatitis (AD) focused attention on the 1q21 locus, where not only FLG but also other epidermal genes are located. In the present study, we compared 1q21 gene expression in lesional versus nonlesional AD skin.


METHODS
A real-time quantitative PCR analysis of 10 1q21 genes, selected on the basis of a previous microarray study, was performed in skin biopsies from 33 individuals with AD. Three alternative pathway keratins were also evaluated.


RESULTS
In chronic AD skin lesions, we observed an increase in RNA encoding involucrin, S100 calcium-binding proteins A2 and A7-A9 and small proline-rich region (SPRR) proteins 1A and 2C, with fold changes ranging from 2.0 for S100A2 to 15.4 for S100A8 (p < 0.001, Bonferroni corrected), in parallel to the overexpression of the alternative pathway keratins 6A, 6B and 16. The loricrin (LOR) expression level was significantly decreased in lesional AD skin (fold change 0.5; p < 0.01). The expression of the majority of 1q21 genes and alternative keratins was closely correlated; however, for SPRR1A (and SPRR2C) in lesional skin, the correlation with other genes was lost.


CONCLUSIONS
We hypothesize that the deregulated increase in SPRR1A expression in chronic atopic skin lesions reflects an insufficient rise in SPRR transcripts, unable to compensate for the lack of LOR and thus contributing to the persistence of chronic AD skin lesions. Turning off the stress response in the skin may be regarded as a goal in the treatment of AD skin lesions, and SPRR genes might be targets for such an approach.
Jarzab
Jerzy
J
Department of Internal Medicine, Dermatology and Allergology, Silesian Medical University, Zabrze, Poland. jerzy.jarzab@gmail.com
Filipowska
Barbara
B
Zebracka
Jadwiga
J
Kowalska
Małgorzata
M
Bozek
Andrzej
A
Rachowska
Regina
R
Gubala
Elzbieta
E
Grzanka
Alicja
A
Hadas
Ewa
E
Jarzab
Barbara
B
D000328:Adult; D002908:Chronic Disease; D055233:Cornified Envelope Proline-Rich Proteins / Q000235:genetics*; D003876:Dermatitis, Atopic / Q000235:genetics* / Q000276:immunology; D005260:Female; D000091344:Filaggrin Proteins; D005786:Gene Expression Regulation; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007381:Intermediate Filament Proteins / Q000276:immunology / Q000378:metabolism; D007633:Keratins / Q000276:immunology / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D011498:Protein Precursors / Q000276:immunology / Q000378:metabolism; D009418:S100 Proteins / Q000235:genetics; D012867:Skin / Q000276:immunology / Q000378:metabolism
D055233:Cornified Envelope Proline-Rich Proteins; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007381:Intermediate Filament Proteins; D008565:Membrane Proteins; D011498:Protein Precursors; D009418:S100 Proteins; C524531:SPRR1A protein, human; C524773:SPRR2C protein, human; C064554:loricrin; D007073:Immunoglobulin E; C032253:involucrin; D007633:Keratins